Ann Oncol 2017; 28: iv72-iv83 (doi:10.1093/annonc/mdx220) Under the section "Adjuvant treatment" Adjuvant treatment Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of risk are defined: intermediate- and high-risk patients. Is replaced with: Adjuvant treatment (Table 3) Two classes of risk are defined: intermediate- and high-risk patients. In "Table 5. Summary of recommendations" Adjuvant treatment • Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3). • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A]. Is replaced with: Adjuvant treatment • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].

Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2018). Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) [Altro] [10.1093/annonc/mdy160].

Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220)

F. Landoni;N. Colombo
2018

Abstract

Ann Oncol 2017; 28: iv72-iv83 (doi:10.1093/annonc/mdx220) Under the section "Adjuvant treatment" Adjuvant treatment Women with risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (Table 3). Two classes of risk are defined: intermediate- and high-risk patients. Is replaced with: Adjuvant treatment (Table 3) Two classes of risk are defined: intermediate- and high-risk patients. In "Table 5. Summary of recommendations" Adjuvant treatment • Women with intermediate- and high-risk factors on the pathology specimen should receive adjuvant therapy following hysterectomy (see Table 3). • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A]. Is replaced with: Adjuvant treatment • Cervical cancer patients with intermediate-risk disease do not need further adjuvant therapy [II, B], whereas adjuvant CRT is recommended in high-risk patients [I, A].
Altro
Si
Scientifica
Cervical Cancer; Hematology; Oncology; Follow-up, Guidelines, Management, Staging; Erratum
English
Publication type: Published Erratum Scopus ID 2-s2.0-85054407615 - Wos ID WOS:000448047900020 - PubMed ID 32169233/29741577
Marth, C., Landoni, F., Mahner, S., McCormack, M., Gonzalez-Martin, A., & Colombo, N. (2018). Erratum: Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (Annals of Oncology (2017) 28 (iv72-iv83) DOI: 10.1093/annonc/mdx220) [Altro] [10.1093/annonc/mdy160].
Marth, C; Landoni, F; Mahner, S; Mccormack, M; Gonzalez-Martin, A; Colombo, N
File in questo prodotto:
File Dimensione Formato  
10281-265047.pdf

accesso aperto

Tipologia di allegato: Publisher’s Version (Version of Record, VoR)
Dimensione 61 kB
Formato Adobe PDF
61 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/265047
Citazioni
  • Scopus 53
  • ???jsp.display-item.citation.isi??? 51
Social impact